Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes clinical resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes adverse effects compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
The review found no eligible studies for this question.
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes pain resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary patency ( · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE showed no clear difference in primary patency (24 months) compared with dacron (low certainty).
2 findings from 1 review
OR 1.23 [0.92, 1.65]
Studies not reported
Low
OR 1.67 [0.96, 2.9]
Studies not reported
Low
Secondary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE may leads to higher secondary patency (24 months) compared with dacron (low certainty).
1 finding from 1 review
OR 1.54 [1.04, 2.28]
Studies not reported
Low
Limb salvage · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE showed no clear difference in limb salvage (24 months) compared with dacron (low certainty).
1 finding from 1 review
OR 0.82 [0.27, 2.48]
Studies not reported
Low
Death or dependence · people with subarachnoid haemorrhage from a ruptured intracranial aneurysm
Endovascular coiling probably leads to lower poor outcome: death or dependence in daily activities (12 months) compared with neurosurgical clipping (moderate certainty).
2 findings from 1 review
Death from any cause (12 months) · people with subarachnoid haemorrhage from a ruptured intracranial aneurysm
Endovascular coiling showed no clear difference in death from any cause (12 months) compared with neurosurgical clipping (moderate certainty).
1 finding from 1 review
Delayed cerebral ischaemia · people with subarachnoid haemorrhage from a ruptured intracranial aneurysm
Endovascular coiling probably leads to lower delayed cerebral ischaemia (2–3 months) compared with neurosurgical clipping (moderate certainty).
1 finding from 1 review
Rebleeding · people with subarachnoid haemorrhage from a ruptured intracranial aneurysm
Endovascular coiling leads to higher rebleeding postprocedure up to 1 year compared with neurosurgical clipping (high certainty).
2 findings from 1 review
Complications from the intervention · people with subarachnoid haemorrhage from a ruptured intracranial aneurysm
Endovascular coiling showed no clear difference in complications from the intervention compared with neurosurgical clipping (low certainty).
1 finding from 1 review
Onset of PDPH · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles may leads to lower onset of PDPH compared with smaller atraumatic needles (low certainty).
1 finding from 1 review
Paraesthesia · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles probably leads to lower adverse events: paraesthesia compared with smaller atraumatic needles (moderate certainty).
1 finding from 1 review
Adverse events: backache · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles probably leads to lower adverse events: backache compared with smaller atraumatic needles (moderate certainty).
1 finding from 1 review
Severe PDPH · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles showed no clear difference in severe PDPH compared with smaller atraumatic needles (low certainty).
1 finding from 1 review
Headache · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles probably leads to lower any headache compared with smaller atraumatic needles (moderate certainty).
1 finding from 1 review
Overall pain · rotator cuff disease
1 finding from 1 review